CLINICAL TRIAL / NCT06182579

Inclusion Criteria: - Diagnosis of advanced or metastatic cancer not amenable to curative therapy - Lesion that is amenable to palliative radiotherapy - Lesion that is technically feasible for intratumoral injection - Target tumor in region not in the field that was irradiated within the past six months - Patients with advanced or metastatic HNSCC must have progressed on or been intolerant to standard of care therapies including platinum-based chemotherapy and anti-PD(L)1 therapy, prior to study enrollment - Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment - Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion - ECOG score of 0-1 - Have a life expectancy of at least 12 weeks - Have adequate bone marrow reserve and adequate liver function - Both males and females and their partners of childbearing potential must agree to use adequate contraceptive measures - Patients must sign a study-specific informed consent form prior to study entry - Age 18 years or older. Exclusion Criteria: - Patients with a histological diagnosis of lymphomas and/or leukemias - Patients with significant blood vessels (such as carotid artery encasement) or other major structures in the tumor region to be injected - Patients may not have received chemotherapy, targeted therapies, immunotherapies, biologic response modifiers and/or hormonal therapy within the last 14 days - Ongoing clinically significant infection at or near the incident lesion - Major surgery over the target area (excluding placement of vascular access) <21 days from beginning of the study drug or minor surgical procedures <7 days - Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study - Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial - Pregnant and nursing women - Patients with a target lesion located in a previously irradiated field - Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation.